B-I09 | CAS#1607803-67-7

MedKoo Cat#: 525366 | Name: B-I09

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

B-I09 is a novel cell permeable IRE-1 RNase inhibitor, blocking IRE-1/XBP1 pathway.

Chemical Structure

B-I09

CAS#1607803-67-7

Theoretical Analysis

MedKoo Cat#: 525366

Name: B-I09

CAS#: 1607803-67-7

Chemical Formula: C16H17NO5

Exact Mass: 303.1107

Molecular Weight: 303.31

Elemental Analysis: C, 63.36; H, 5.65; N, 4.62; O, 26.37

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 450.00	2 Weeks
50mg	USD 1,050.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

B-I09; B-I 09; B-I-09; BI09;

IUPAC/Chemical Name

7-(1,3-Dioxan-2-yl)-1,2,3,4-tetrahydro-8-hydroxy-5H-[1]benzopyrano[3,4-c]pyridin-5-one

InChi Key

UYYMWNUDIOPESF-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H17NO5/c18-12-3-2-10-9-4-5-17-8-11(9)15(19)22-14(10)13(12)16-20-6-1-7-21-16/h2-3,16-18H,1,4-8H2

SMILES Code

O=C1OC2=C(C3OCCCO3)C(O)=CC=C2C4=C1CNCC4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

B I09 is an IRE-1 RNase inhibitor with an IC50 of 1.23 μM.

In vitro activity:

B-I09, an inositol-requiring enzyme-1α (IRE1α) inhibitor that prevents XBP-1 splicing, reduced human moDC (monocyte-derived dendritic cell) migration, allo-stimulatory potency, and curtailed moDC IL-1β, TGFβ, and p40 cytokines, suppressing Th1 and Th17 cell priming. B-I09-treated moDCs reduce responder T cell activation via calcium flux without interfering with regulatory T cell (Treg) function or GVL (graft- vs.-leukemia) effects by cytotoxic T lymphocytes (CTL) and NK cells. Reference: Front Immunol. 2018 Dec 6;9:2887. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291501/

In vivo activity:

In a human T cell mediated xenogeneic GVHD (graft- vs. -host disease) model, B-I09 inhibition of XBP-1s reduced target-organ damage and pathogenic Th1 and Th17 cells without impacting donor Tregs or anti-tumor CTL. Reference: Front Immunol. 2018 Dec 6;9:2887. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291501/

	Solvent	mg/mL	mM
Solubility
	DMSO	11.8	38.74

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 303.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Betts BC, Locke FL, Sagatys EM, Pidala J, Walton K, Menges M, Reff J, Saha A, Djeu JY, Kiluk JV, Lee MC, Kim J, Kang CW, Tang CH, Frieling J, Lynch CC, List A, Rodriguez PC, Blazar BR, Conejo-Garcia JR, Del Valle JR, Hu CC, Anasetti C. Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. Front Immunol. 2018 Dec 6;9:2887. doi: 10.3389/fimmu.2018.02887. PMID: 30574153; PMCID: PMC6291501.

In vitro protocol:

In vivo protocol:

1: Tang CH, Ranatunga S, Kriss CL, Cubitt CL, Tao J, Pinilla-Ibarz JA, Del Valle JR, Hu CC. Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival. J Clin Invest. 2014 Jun;124(6):2585-98. doi: 10.1172/JCI73448. Epub 2014 May 8. PubMed PMID: 24812669; PubMed Central PMCID: PMC4038575.